Aptamer Binding to Sickle Hemoglobin Polymerization Interface

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for sickle cell anemia are complex and labor-intensive, primarily focusing on palliative care with methods like bone marrow transplantation, routine blood transfusions, and hydroxyurea, which only indirectly and incompletely address the polymerization of sickle hemoglobin, leading to significant morbidity and mortality.

Innovation Solution

Development of polynucleotide aptamers, specifically RNA aptamers, that bind to sickle hemoglobin (HbS) to inhibit its polymerization without affecting hemoglobin's functional capabilities, offering a therapeutic and diagnostic approach by targeting both oxygenated and deoxygenated forms of HbS.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If bone marrow transplantation, routine blood transfusions, or hydroxyurea are used to treat sickle cell anemia, then the severity of the disorder is altered, but the treatments are complex and labor intensive

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidcomplexity of treatment

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent extracts and targets the specific pathological mechanism (HbS polymerization) rather than treating the overall disease complexity. By isolating the polymerization process as the primary target and using aptamers to specifically inhibit this mechanism, the treatment simplifies the approach while maintaining effectiveness against the core pathology of sickle cell anemia

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The invention changes the therapeutic parameter from indirect modulation (hydroxyurea inducing fetal hemoglobin) to direct inhibition (aptamers binding to HbS polymerization interfaces). This parameter shift from indirect to direct action reduces treatment complexity while improving reliability by targeting the actual polymerization mechanism

Inventive Principle:

Principle #35Parameter changes

2Reliability

If hydroxyurea is used to prevent HbS polymerization by inducing fetal hemoglobin production, then polymerization is indirectly prevented, but the prevention is incomplete

Engineering Contradiction:

Improvepolymerization preventionVSAvoiddirectness of mechanism

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent uses aptamers as direct intermediary molecules that bind to HbS at the polymerization interface, preventing polymer formation without requiring induction of fetal hemoglobin. This eliminates the incomplete prevention issue by directly blocking the polymerization pathway rather than relying on indirect mechanisms

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention replaces the biochemical mechanism of hydroxyurea (inducing fetal hemoglobin production) with a direct physical blocking mechanism (aptamer binding to HbS polymerization sites). This substitution provides complete and direct prevention of polymerization without the limitations of indirect induction

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Reliability

If aptamers bind to HbS to inhibit polymerization, then polymerization is inhibited, but hemoglobin's functional capabilities must be preserved

Engineering Contradiction:

Improvepolymerization inhibitionVSAvoidimpact on hemoglobin function

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by designing aptamers that bind specifically to the polymerization interface of HbS molecules without interfering with the oxygen-binding sites. This localized binding approach allows complete polymerization inhibition while preserving the essential oxygen transport function of hemoglobin

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The aptamers are designed to replicate and block the polymerization interface structure without affecting other functional regions of HbS. By copying only the relevant polymerization interface features, the aptamers achieve specific inhibition while leaving oxygen-binding and other functional capabilities intact

Inventive Principle:

Principle #26Copying

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The aptamers effectively inhibit HbS polymerization, potentially reducing disease symptoms and complications, providing a more direct and effective treatment for sickle cell anemia while allowing for diagnostic applications.

Implementation Method 1

polynucleotide aptamers that specifically bind sickle hemoglobin (HbS) in such a way that polymerization of HbS is inhibited

Methodology Applied

Scientific EffectMolecular recognition and binding: Adsorption

Data Source

PatentUS11214804B2Aptamers for the treatment of sickle cell disease

Publication Date: 2022.01.04 JOHNS HOPKINS UNIVERSITY

AI summary

The present invention provides polynucleotide aptamers that selectively bind to and inhibit polymerization of sickle hemoglobin (HbS), pharmaceutical compositions comprising the same, methods of use for diagnostics and treatment of sickle cell disease, methods of use as capture reagents, and methods of rational drug design.